Stockscreener 앱 받기
0.8793
1.72%
0.0149
Lineage Cell Therapeutics Inc 주식(LCTX)의 최신 뉴스
Lineage Cell Therapeutics initiated with a Buy at D. Boral Capital - TipRanks
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highl - GuruFocus.com
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q3 2024 Earnings Call Transcript - Insider Monkey
Lineage Cell: Q3 Earnings Snapshot - Houston Chronicle
Lineage Cell Therapeutics Reports Q3 2024 Highlights - TipRanks
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings: EPS of -$0.02, Revenue Surges to $3.8M, Beating Estimates - GuruFocus.com
Lineage Cell Therapeutics reports Q3 EPS (2c), consensus (3c) - TipRanks
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - StockTitan
Lineage Cell Therapeutics's Earnings Outlook - Benzinga
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 - BioSpace
Lineage Cell Therapeutics to Report Q3 2024 Earnings on November 14 | LCTX Stock News - StockTitan
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? - Yahoo Finance
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit - Business Wire
Dendritic Cell Cancer Vaccine Immunotherapy Market Growing Rapidly by-Lineage Cell Therapeutics, AVAX Technologies, DCPr – IndiaPolitics.com - IndiaPolitics.com
Lineage Cell Therapeutics Inc [LCTX] Shares Fall -3.95 % on Thursday - Knox Daily
Lineage Cell Therapeutics Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
Investor’s Toolkit: Key Ratios for Assessing Lineage Cell Therapeutics Inc (LCTX)’s Performance - The Dwinnex
Lineage Looking to Restore Sight, Hearing, Movement - San Diego Business Journal
Allogeneic Stem Cells Market on Track for Strong Growth by 2031 | - openPR
Lineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ... - Yahoo Finance
What Makes Lineage Cell (LCTX) a New Buy Stock - Yahoo Finance
ORBCOMM joins Move to -15°C coalition to promote cold chain sustainability - GlobeNewswire Inc.
Are Smart Investors Making the Right Decision? Lineage Cell Therapeutics Inc (LCTX) - SETE News
Baird maintains Outperform rating on Lineage Cell shares - Investing.com India
Understanding the Risks of Investing in Lineage Cell Therapeutics Inc (LCTX) - Knox Daily
Market Insights: Lineage Cell Therapeutics Inc (LCTX)’s Notable Drop of -1.60, Closing at 0.91 - The Dwinnex
Have you been able to find a good deal on Lineage Cell Therapeutics Inc’s shares? - US Post News
Logos Global Management LP Has $4.69 Million Stock Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - MarketBeat
Cell Theraputics Industry Analysis by Regions, Types and Application - Elektrotransports.lv
LCTXLineage Cell Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium - Business Wire
Raffles Associates LP Increases Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Cell Therapeutics Inc [LCTX] Investment Guide: What You Need to Know - Knox Daily
Global Autologous Cell Therapy Product Market Projected to Reach USD 40.77 Billion by 2032 with a 16.9% CAGR - 대구포스트
Longevity and Anti-Senescence Therapy Market Share, Size, Growth, and Forecast to 2031 - InsightAce Analytic
Lineage Cell Therapeutics Reports Successful Preclinical Results for Cell-Based Therapy for Hearing Loss - The Hearing Review
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop - StockTitan
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance - Business Wire
A Guide To The Risks Of Investing In Lineage Cell Therapeutics Inc (LCTX) - Knox Daily
Autologous Cell Therapy Product Market is Estimated to Reach USD 40.77 Billion By 2032 | Vantage Market Research - 대구포스트
Lineage Cell Therapeutics Inc [LCTX] Records 200-Day SMA of $1.0619 - Knox Daily
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Sees Significant Growth in Short Interest - MarketBeat
Allogeneic Stem Cells Market to Witness Huge Growth by 2031 - openPR
Lineage Cell Therapeutics Inc (LCTX) gets rating Initiated from Craig Hallum - Knox Daily
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Coverage Initiated by Analysts at Craig Hallum - Defense World
Lineage Cell Therapeutics stock upgraded to buy on OpRegen potential - Investing.com
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Earns Buy Rating from Analysts at Craig Hallum - MarketBeat
Lineage Cell Therapeutics CFO buys $9,345 in company stock - Investing.com
Lineage Cell Therapeutics CFO buys $9,345 in company stock By Investing.com - Investing.com UK
A company insider recently bought 10,000 shares of Lineage Cell Therapeutics Inc [LCTX]. Should You Buy? - Knox Daily
Comerica Bank Raises Stock Holdings in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) - Defense World
Lineage Cell Therapeutics (FRA:BT3) Financial Strength : 5 (As of Jun. 2024) - GuruFocus.com
What is Lineage Cell Therapeutics Inc (LCTX) Stock Return on Shareholders’ Capital? - SETE News
FY2024 Earnings Forecast for Lineage Cell Therapeutics, Inc. Issued By Cantor Fitzgerald (NYSEAMERICAN:LCTX) - MarketBeat
Is Lineage Cell Therapeutics Inc (LCTX) worth investing in despite its undervalued state? - US Post News
Analysts Set Expectations for Lineage Cell Therapeutics, Inc.’s FY2024 Earnings (NYSEAMERICAN:LCTX) - Defense World
Robert W. Baird’s latest rating for LCTX stock - Knox Daily
Lineage Cell Therapeutics Inc (LCTX) Stock: Navigating Drops and Gains - The InvestChronicle
3.66%
1.11%
자본화:
|
볼륨(24시간):